Novo Nordisk's (NOVOB DC) CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 Trial

Novo Nordisk's latest trial results for CagriSema indicate a significant improvement in HbA1c reduction and weight loss for adults with type 2 diabetes.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily Economic Releases - 3rd February 2026

US Ambassador to India says that US President Trump has spoken with India's PM Modi

Novo Nordisk's (NOVOB DC) CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 Trial

US President Trump has built a USD 484mln war chest ahead of the midterm elections, via Campaign finance filing

Oracle (ORCL) is reportedly seeking a USD 5bln in convertible bond issue

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This strong performance could bolster the company's position in the diabetes treatment market, potentially attracting greater investor interest and impacting their stock positively, especially if future guidance reflects these outcomes.

Related headlines

The whole workspace, free to try.

Try it free